Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mammalian Target of Rapamycin Signaling and Autophagy: Roles in Lymphangioleiomyomatosis Therapy

1 Feb 2010

Abstract excerpt

The pace of progress in lymphangioleiomyomatosis (LAM) is remarkable. In the year 2000, TSC2 gene mutations were found in LAM cells; in 2001 the tuberous sclerosis complex (TSC) genes were discovered to regulate cell size in Drosophila via the kinase TOR (target of rapamycin); and in 2008 the results were published of a clinical trial of rapamycin, a specific inhibitor of TOR, in patients with TSC and LAM with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Tuberous Sclerosis Complex Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 20160148
DOI: 10.1513/pats.200909-104js

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mammalian Target of Rapamycin Signaling and Autophagy: Roles in Lymphangioleiomyomatosis TherapyPMID 20160148Read ↗

AutophagySemantic proximity Read ↗

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)Semantic proximity Read ↗

Clinical and molecular insights into lymphangioleiomyomatosis.Semantic proximity Read ↗

Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.Semantic proximity Read ↗

Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.Semantic proximity Read ↗

TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis ComplexSemantic proximity Read ↗

mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complexSemantic proximity Read ↗

Extracellular Matrix-Induced Genes May Reduce Response to Rapamycin in LAMSemantic proximity Read ↗

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.Semantic proximity Read ↗

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Semantic proximity Read ↗

Lymphangioleiomyomatosis: Current understanding and potential treatments.Semantic proximity Read ↗

Combination of Volasertib and Rapamycin Inhibits the Regrowth of TSC2-Deficient TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.